Rita Nanda

Rita Nanda, MD, is an Associate Professor of Medicine and Director of Breast Oncology at The University of Chicago. Her research focuses on identifying novel treatments for the management of breast cancer, particularly triple-negative disease. She leads The University of Chicago’s clinical and translational breast cancer research efforts, and serves as a Principal Investigator and Chair of the Triple-Negative Working Group for the Translational Breast Cancer Research Consortium (TBCRC) and is Principal Investigator and Chair of the Safety Working Group for the ISPY2 Clinical Trial Network.

Dr. Nanda has authored numerous scientific publications and book chapters, including one of the first reports of immune checkpoint inhibitor therapy for triple-negative breast cancer. Her research has been funded by The NIH, The Department of Defense Breast Cancer Research Program, The Doris Duke Charitable Foundation, The Susan G. Komen Foundation, and The Metastatic Breast Cancer Network, and the Lynn Sage Breast Cancer Foundation. In 2014, she was awarded the NCI Cancer Clinical Investigator Team Leadership Award and in 2023 the Doris Duke Foundation Paragon Award for Research Excellence.